Recently, a clinical study reported by Kratochwil et al. demonstrated the remarkable anti-tumor effect of [225Ac]Ac-PSMA-617 (100 kBq/kg) in 81% of metastatic castration-resistant PCa patients [303]. This evidence concerns the gene FOLH1 and neoplasm.